Perioperative complications and risk factors after neoadjuvant immunotherapy for patients with gastric cancer
10.3760/cma.j.cn113855-20240809-00521
- VernacularTitle:胃癌新辅助化疗免疫治疗后围手术期并发症及其影响因素研究进展
- Author:
Guoshuai CHEN
1
;
Kewei JIANG
Author Information
1. 北京大学人民医院胃肠外科，北京 100044
- Keywords:
Stomach neoplasms;
Chemotherapy, adjuvant;
Immunotherapy;
Complications
- From:
Chinese Journal of General Surgery
2024;39(10):747-751
- CountryChina
- Language:Chinese
-
Abstract:
Currently, gastrectomy+D 2 lymph node dissection has become the standard treatment for advanced gastric cancer, but the 5-year survival rate of gastric cancer patients is still less than 50%. In order to improve the prognosis of patients with advanced gastric cancer, neoadjuvant therapy has emerged. Neoadjuvant chemotherapy has been widely used in the treatment of gastric cancer. At the same time, neoadjuvant immunotherapy (NAI) represented by PD-1 inhibitors has begun to emerge in the treatment of locally advanced gastric cancer. Whether neoadjuvant therapy, especially NAI, inflicts an increased complications after radical resection of gastric cancer is still a matter of sorne concern. Therefore, this article reviews the application of neoadjuvant therapy for gastric cancer, perioperative complications and influencing factors of surgical complications.
